How Well the Constructs of Health Belief Model Predict Vaccination Intention: A Systematic Review on COVID-19 Primary Series and Booster Vaccines.

Yam B Limbu, Rajesh K Gautam
Author Information
  1. Yam B Limbu: Feliciano School of Business, Montclair State University, 1 Normal Ave., Montclair, NJ 07043, USA. ORCID
  2. Rajesh K Gautam: Department of Anthropology, Dr. Harisingh Gour Central University, Sagar 470003, MP, India. ORCID

Abstract

This systematic review synthesizes the findings of quantitative studies examining the relationships between Health Belief Model (HBM) constructs and COVID-19 vaccination intention. We searched PubMed, Medline, CINAHL, Web of Science, and Scopus using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and identified 109 eligible studies. The overall vaccination intention rate was 68.19%. Perceived benefits, perceived barriers, and cues to action were the three most frequently demonstrated predictors of vaccination intention for both primary series and booster vaccines. For booster doses, the influence of susceptibility slightly increased, but the impact of severity, self-efficacy, and cues to action on vaccination intention declined. The impact of susceptibility increased, but severity's effect declined sharply from 2020 to 2022. The influence of barriers slightly declined from 2020 to 2021, but it skyrocketed in 2022. Conversely, the role of self-efficacy dipped in 2022. Susceptibility, severity, and barriers were dominant predictors in Saudi Arabia, but self-efficacy and cues to action had weaker effects in the USA. Susceptibility and severity had a lower impact on students, especially in North America, and barriers had a lower impact on health care workers. However, cues to action and self-efficacy had a dominant influence among parents. The most prevalent modifying variables were age, gender, education, income, and occupation. The results show that HBM is useful in predicting vaccine intention.

Keywords

References

  1. Vaccines (Basel). 2021 Nov 25;9(12): [PMID: 34960138]
  2. Health Serv Res Manag Epidemiol. 2022 Mar 02;9:23333928221083057 [PMID: 35252472]
  3. Vaccines (Basel). 2022 Jun 02;10(6): [PMID: 35746501]
  4. Patient Educ Couns. 2021 Aug;104(8):1878-1886 [PMID: 33632632]
  5. Front Public Health. 2022 Mar 16;10:834572 [PMID: 35372197]
  6. Hum Vaccin Immunother. 2021 Dec 2;17(12):4823-4828 [PMID: 34623931]
  7. PLoS One. 2022 Feb 22;17(2):e0264128 [PMID: 35192664]
  8. Health Psychol. 2007 Mar;26(2):136-45 [PMID: 17385964]
  9. Health Commun. 2023 Oct;38(11):2491-2500 [PMID: 35658753]
  10. Vaccine. 2021 Aug 23;39(36):5116-5128 [PMID: 34340856]
  11. Vaccines (Basel). 2021 Dec 10;9(12): [PMID: 34960208]
  12. Vaccines (Basel). 2022 Apr 14;10(4): [PMID: 35455358]
  13. Vaccines (Basel). 2022 Aug 17;10(8): [PMID: 36016224]
  14. Int J Clin Pharm. 2022 Feb;44(1):247-255 [PMID: 34761359]
  15. Vaccines (Basel). 2021 Nov 30;9(12): [PMID: 34960161]
  16. Res Social Adm Pharm. 2023 Jan;19(1):95-101 [PMID: 36153237]
  17. J Educ Health Promot. 2022 Jun 11;11:175 [PMID: 35847130]
  18. Int J Environ Res Public Health. 2022 Jan 14;19(2): [PMID: 35055740]
  19. Front Public Health. 2022 Jul 25;10:938067 [PMID: 35958845]
  20. Vaccines (Basel). 2022 Jul 21;10(7): [PMID: 35891323]
  21. Vaccines (Basel). 2022 Dec 20;11(1): [PMID: 36679849]
  22. Vaccines (Basel). 2022 May 16;10(5): [PMID: 35632540]
  23. Front Psychol. 2022 Jan 21;12:783374 [PMID: 35126238]
  24. Vaccines (Basel). 2021 Aug 29;9(9): [PMID: 34579204]
  25. Front Public Health. 2021 Nov 02;9:715931 [PMID: 34796158]
  26. Vaccines (Basel). 2022 May 05;10(5): [PMID: 35632482]
  27. Vaccine. 2020 Sep 29;38(42):6500-6507 [PMID: 32863069]
  28. Front Public Health. 2022 Mar 30;10:842862 [PMID: 35433579]
  29. Hum Vaccin Immunother. 2020 Sep 1;16(9):2204-2214 [PMID: 32730103]
  30. J Multidiscip Healthc. 2021 May 18;14:1119-1128 [PMID: 34040382]
  31. PeerJ. 2022 Feb 16;10:e12887 [PMID: 35190785]
  32. Front Public Health. 2022 Dec 15;10:986916 [PMID: 36589991]
  33. J Clin Nurs. 2022 Jan;31(1-2):62-86 [PMID: 34227179]
  34. Health Commun. 2023 Jul;38(8):1530-1539 [PMID: 35081848]
  35. Front Public Health. 2022 Nov 04;10:957721 [PMID: 36438218]
  36. Hum Vaccin Immunother. 2021 Dec 2;17(12):4829-4837 [PMID: 34714726]
  37. Int J Infect Dis. 2022 Jan;114:1-10 [PMID: 34597765]
  38. Vaccines (Basel). 2022 Jan 04;10(1): [PMID: 35062738]
  39. Vaccines (Basel). 2022 Apr 22;10(5): [PMID: 35632415]
  40. Prev Med. 2021 Sep;150:106694 [PMID: 34171345]
  41. Tour Manag. 2022 Feb;88:104405 [PMID: 34456412]
  42. Risk Manag Healthc Policy. 2021 Jun 28;14:2743-2756 [PMID: 34234590]
  43. Front Med (Lausanne). 2022 Jun 03;9:890503 [PMID: 35721100]
  44. Vaccine. 2022 Feb 16;40(8):1074-1081 [PMID: 35090777]
  45. PLoS One. 2022 Feb 11;17(2):e0262305 [PMID: 35148317]
  46. Int J Environ Res Public Health. 2010 Mar;7(3):853-69 [PMID: 20617008]
  47. Vaccines (Basel). 2023 Feb 12;11(2): [PMID: 36851298]
  48. Asia Pac J Public Health. 2021 Jul;33(5):598-602 [PMID: 34000877]
  49. Vaccines (Basel). 2022 Jan 07;10(1): [PMID: 35062750]
  50. Int J Environ Res Public Health. 2022 Sep 05;19(17): [PMID: 36078836]
  51. BMC Public Health. 2021 Apr 26;21(1):804 [PMID: 33902501]
  52. Transl Behav Med. 2021 Sep 15;11(9):1782-1788 [PMID: 34293163]
  53. Psychol Health Med. 2022 Feb;27(2):379-388 [PMID: 33906540]
  54. Vaccines (Basel). 2021 Jul 13;9(7): [PMID: 34358199]
  55. PLoS One. 2022 Jul 8;17(7):e0270768 [PMID: 35802742]
  56. Vaccines (Basel). 2021 Oct 25;9(11): [PMID: 34835174]
  57. Appl Psychol Health Well Being. 2021 May;13(2):469-484 [PMID: 33634930]
  58. Vaccine. 2022 Apr 26;40(19):2772-2780 [PMID: 35339306]
  59. Expert Rev Pharmacoecon Outcomes Res. 2022 Jul;22(5):753-761 [PMID: 35192425]
  60. Int J Environ Res Public Health. 2022 Mar 20;19(6): [PMID: 35329392]
  61. Vaccines (Basel). 2022 May 11;10(5): [PMID: 35632516]
  62. PLoS Negl Trop Dis. 2020 Dec 17;14(12):e0008961 [PMID: 33332359]
  63. Vaccines (Basel). 2021 Apr 21;9(5): [PMID: 33919254]
  64. Vaccines (Basel). 2022 Jun 21;10(7): [PMID: 35891150]
  65. J Clin Epidemiol. 2016 Jan;69:225-34 [PMID: 26092286]
  66. BMJ Open. 2023 Mar 23;13(3):e070551 [PMID: 36958789]
  67. Vaccines (Basel). 2022 Oct 20;10(10): [PMID: 36298627]
  68. Pharm Pract (Granada). 2021 Jan-Mar;19(1):2276 [PMID: 33828622]
  69. Hum Vaccin Immunother. 2021 Dec 2;17(12):5242-5254 [PMID: 34919492]
  70. Psychol Health Med. 2023 Jan;28(1):161-170 [PMID: 35352590]
  71. Prev Med Rep. 2021 Dec 16;25:101673 [PMID: 34934611]
  72. Am J Infect Control. 2021 Feb;49(2):137-142 [PMID: 33227323]
  73. Int J Environ Res Public Health. 2022 Mar 24;19(7): [PMID: 35409568]
  74. Int J Environ Res Public Health. 2021 Sep 04;18(17): [PMID: 34501932]
  75. Z Gesundh Wiss. 2022 Jan 07;:1-25 [PMID: 35018277]
  76. J Environ Public Health. 2023 Jan 30;2023:6915125 [PMID: 36755775]
  77. Cureus. 2022 Aug 23;14(8):e28326 [PMID: 36168376]
  78. Inquiry. 2022 Jan-Dec;59:469580221082787 [PMID: 35352982]
  79. J Eval Clin Pract. 2021 Oct;27(5):1112-1122 [PMID: 33960582]
  80. J Clin Epidemiol. 2009 Oct;62(10):e1-34 [PMID: 19631507]
  81. Hum Vaccin Immunother. 2021 Oct 3;17(10):3433-3440 [PMID: 34289316]
  82. Vaccines (Basel). 2022 Nov 26;10(12): [PMID: 36560436]
  83. Vaccine. 2022 May 9;40(21):2949-2959 [PMID: 35414417]
  84. PLoS One. 2021 Jun 24;16(6):e0253499 [PMID: 34166399]
  85. Res Social Adm Pharm. 2021 Sep;17(9):1596-1605 [PMID: 33431259]
  86. Vaccines (Basel). 2022 Dec 31;11(1): [PMID: 36679940]
  87. Public Health. 2021 Sep;198:200-207 [PMID: 34481275]
  88. BMC Public Health. 2022 Apr 28;22(1):854 [PMID: 35484522]
  89. Front Psychol. 2021 Sep 14;12:729803 [PMID: 34594282]
  90. BMC Infect Dis. 2022 Mar 4;22(1):218 [PMID: 35246072]
  91. Vaccines (Basel). 2021 Jun 25;9(7): [PMID: 34202016]
  92. Front Psychol. 2021 Jul 12;12:674018 [PMID: 34322062]
  93. Ir J Med Sci. 2022 Oct;191(5):2369-2383 [PMID: 34826039]
  94. Vaccine. 2022 Mar 1;40(10):1404-1412 [PMID: 35131135]
  95. Int J Environ Res Public Health. 2022 Sep 25;19(19): [PMID: 36231447]
  96. Vaccines (Basel). 2022 Feb 14;10(2): [PMID: 35214746]
  97. Vaccines (Basel). 2021 May 06;9(5): [PMID: 34066476]
  98. Vaccines (Basel). 2022 Jun 18;10(6): [PMID: 35746581]
  99. J Clin Epidemiol. 2021 Jun;134:103-112 [PMID: 33577987]
  100. Trop Med Infect Dis. 2023 Mar 05;8(3): [PMID: 36977160]
  101. Vaccines (Basel). 2021 Jul 07;9(7): [PMID: 34358173]
  102. Risk Manag Healthc Policy. 2021 Sep 24;14:4023-4030 [PMID: 34594141]
  103. Res Social Adm Pharm. 2022 Apr;18(4):2593-2599 [PMID: 33994325]
  104. Vaccine. 2022 Oct 26;40(45):6549-6557 [PMID: 36207222]
  105. Vaccines (Basel). 2021 Jun 02;9(6): [PMID: 34199331]
  106. JMIR Public Health Surveill. 2022 Nov 14;8(11):e37203 [PMID: 36219842]
  107. BMC Infect Dis. 2021 Aug 31;21(1):892 [PMID: 34465297]
  108. Fam Syst Health. 2022 Jun;40(2):160-170 [PMID: 35666894]
  109. Vaccine. 2023 Feb 17;41(8):1480-1489 [PMID: 36707336]
  110. Vaccines (Basel). 2021 Dec 28;10(1): [PMID: 35062697]
  111. Vaccines (Basel). 2021 Aug 05;9(8): [PMID: 34451991]
  112. Trop Med Infect Dis. 2022 Oct 21;7(10): [PMID: 36288064]
  113. Hum Vaccin Immunother. 2021 Oct 3;17(10):3441-3449 [PMID: 34402409]
  114. Health Serv Insights. 2021 Dec 2;14:11786329211060130 [PMID: 34880626]
  115. Vaccines (Basel). 2022 Jul 08;10(7): [PMID: 35891265]
  116. Hum Vaccin Immunother. 2021 Dec 2;17(12):4806-4815 [PMID: 34892992]
  117. Hum Vaccin Immunother. 2023 Dec 31;19(1):2186108 [PMID: 36892289]
  118. Vaccines (Basel). 2022 Jul 31;10(8): [PMID: 36016119]
  119. J Med Internet Res. 2021 Sep 6;23(9):e29329 [PMID: 34280115]
  120. J Asian Afr Stud. 2023 Aug;58(5):664-680 [PMID: 37461427]

Word Cloud

Created with Highcharts 10.0.0intentionvaccinationbarrierscuesactionimpactself-efficacyHBMCOVID-19influenceseveritydeclined2022systematicreviewstudiesHealthBeliefModelSystematicpredictorsprimaryseriesboostervaccinessusceptibilityslightlyincreased2020SusceptibilitydominantlowerhealthsynthesizesfindingsquantitativeexaminingrelationshipsconstructssearchedPubMedMedlineCINAHLWebScienceScopususingPreferredReportingItemsReviewsMeta-AnalysesPRISMAguidelinesidentified109eligibleoverallrate6819%Perceivedbenefitsperceivedthreefrequentlydemonstrateddosesseverity'seffectsharply2021skyrocketedConverselyroledippedSaudiArabiaweakereffectsUSAstudentsespeciallyNorthAmericacareworkersHoweveramongparentsprevalentmodifyingvariablesagegendereducationincomeoccupationresultsshowusefulpredictingvaccineWellConstructsPredictVaccinationIntention:ReviewPrimarySeriesBoosterVaccinesboostersbeliefmodel

Similar Articles

Cited By